To determine the effect of latanoprost on the expression of human matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the ciliary body. METHODS. Total RNA was isolated, and qualitative RT-PCR was performed to detect the mRNA of MMPs and TIMPs in human ciliary body tissue and explant cultures of ciliary body smooth muscle (CBSM) cells. CBSM cell cultures were treated with vehicle control or latanoprost acid for 24 hours. Quantitative RT-PCR of cell cultures from five different donors was performed to determine relative changes in expression. GAPDH served as an endogenous control. RESULTS. The mRNA of , and -24 as well as TIMP-1 to -4 were found in ciliary body tissue and CBSM cells. MMP-9 was present after latanoprost treatment. In control CBSM cells, the relative expression of MMP mRNA was MMP-2 and -14 Ͼ MMP-24 Ͼ MMP-1, -11, -15, -16, and -19 Ͼ MMP-3 and 17, Ͼ MMP-12. The relative expression of TIMP mRNA was TIMP-2 Ͼ TIMP-1 Ͼ TIMP-3 Ͼ TIMP-4. Latanoprost increased MMP-3 (in three of five cultures), MMP-17 (in four of five cultures), and TIMP-3 (in all five cultures); MMP-1, -2, -12, -14, -15, and -16 and TIMP-4 were downregulated. CONCLUSIONS. The transcription of the genes for MMP-3 and -17 is increased by latanoprost treatment. MMP-9 is present after latanoprost treatment and may also mediate ECM changes. TIMP-3 is upregulated and may compensate for the increase in MMPs. These coordinated changes could be expected to mediate the latanoprost-induced alteration of ECM in the ciliary body. (Invest Ophthalmol Vis Sci. 2006;47:953-963)
I
n the United States, glaucoma is the second leading cause of irreversible visual impairment. [1] [2] [3] The only rigorously validated treatment in humans is the lowering of intraocular pressure (IOP). 4 -9 Latanoprost is a most effective topical IOPlowering medication. 10 -12 Latanoprost lowers IOP by increasing uveoscleral outflow up to 60%. [13] [14] [15] [16] [17] The increased facility of outflow is believed to be the result of increased space around ciliary body smooth muscle (CBSM) cells caused by a PGF 2␣ analogue-mediated alteration of the extracellular matrix (ECM) after 4 to 8 days of treatment.
18, 19 The increased ECM turnover in the ciliary body (CB) is thought to be the result of increased expression and release of matrix metalloproteinases (MMPs) by CBSM cells.
MMPs are zinc-dependent endopeptidases that are collectively capable of degrading many ECM components. 20 To date, there are at least 21 unique MMPs divided into five subfamilies in humans: collagenases, stromelysins, gelatinases, membranetype (MT)-MMPs, and miscellaneous others. 21 Although there is significant substrate overlap, the subfamilies of MMPs are defined by the their ability to degrade certain ECM components. Five MMPs (i.e., MMP-1, -2, -3, -9, and -14) and three tissue inhibitors of matrix metalloproteinases (TIMPs; i.e., TIMP-1, -2, and -3) have been described in the CB, whereas only four MMPs (i.e., MMPs -1, -2, -3, and -9) and two TIMPs (i.e., TIMP-1 and -2) have been studied with regard to their response to latanoprost. [22] [23] [24] [25] [26] MMPs can be regulated at transcription, translation, and activation and through inhibition at the active site by TIMPs. For most MMPs, with the notable exception of MMP-2, transcriptional regulation and kinetic inhibition by TIMPs predominate. 20 TIMPs are kinetic inhibitors of MMP enzymatic activity and, in some cases, are involved in the activation of MMPs from their inactive zymogen form to their active form. TIMP-2, 3, and -4 can bind pro-MMP-2, whereas TIMP-1 and -3 can bind pro-MMP-9. 27 Four mammalian TIMPs have been described. All four bind all known activated MMPs, although TIMP-1 poorly inhibits MMP-14, -15, -16, -19, and -24. 27, 28 In many tissues, the ratio of MMPs to TIMPs ultimately determines the rate of ECM turnover. 29 -37 Our long-term goal is to determine the MMP-to-TIMP ratios that are associated with the observed increased uveoscleral outflow. In this investigation, we determined the presence of transcripts of MMPs and TIMPs expressed at baseline and determined the relative changes in transcription after incubation with latanoprost in human CBSM cells, to ascertain which MMPs and TIMPs are critical in regulating outflow resistance.
MATERIALS AND METHODS

Tissue and Explant Culture
All ciliary bodies were dissected from human donor corneoscleral buttons harvested within 12 hours after death. The corneoscleral buttons were removed by the Lyons Eye Bank of Delaware Valley (Philadelphia, PA) and stored (Optisol-GS; Bausch & Lomb Surgical, Irvine, CA) in accordance with the guidelines set forth in the Declaration of Helsinki. We have shown the suitability of corneoscleral buttons for molecular biological studies. 38 The CB tissue was dissected from the anterior segment and placed in Ϫ80°C for no longer than 2 weeks before isolation of RNA. We isolated CB tissue from 23 CBSM cells were cultured according to a previously published protocol. 39 The cultures were maintained in Dulbecco's modified Eagle's medium (DMEM; BioWhittaker; Walkersville, MD) containing 20% fetal bovine serum, 1% L-glutamine (2 mM), and gentamicin (0.1 mg/ mL; all from Gibco-Invitrogen, Carlsbad, CA) at 37°C in 10% CO 2 . Cell identity-confirmatory immunohistochemistry, labeling with antidesmin and anti-smooth muscle actin antibodies, of our cultured cells was consistent with CBSM cells. 39 All the cells used were from passage-4 cultures.
Latanoprost Incubation
Stock solutions of 10 mM latanoprost free acid (Cayman Chemical, Ann Arbor, MI) were prepared in ethanol and diluted to experimental concentrations with serum-free medium. CBSM cells (1 ϫ 10 6 ) were plated into T-75 flasks and allowed to grow to confluence. Once confluent, the cultures were maintained for 1 week. The cells were then incubated with serum-free medium for 48 hours and then exposed to ethanol (0.06%, the vehicle control), 0.03, 0.3, and 30 g/mL of latanoprost free acid for 24 hours. In studies of human uveal and cutaneous melanoma cell lines, concentrations of 10 g/mL reliably showed changes in tyrosinase and cyclic AMP levels. We chose 30 g/mL in the event that no trend was observed at 0.03 or 0.3 g/mL, to see the trend at a dose far in excess of the pharmacological one. 40 In practice, latanoprost is given as a 0.005% (50 g/mL) topical solution, resulting in a peak aqueous concentration of latanoprost free acid of 78 nM (0.028 g/mL, 28 ng/mL) 1 to 2 hours after administration (the half-life in aqueous humor is 2 to 3 hours). 41 The cells were then scraped for RNA extraction.
RNA Isolation
RNA was extracted (RNAqueous-4PCR kit; Ambion, Austin, TX) in accordance with the manufacturer's protocol. Briefly, the tissue (or cell pellet) was lysed with a guanidinium thiocyanate-containing buffer to inactivate RNase and then homogenized. Total RNA was isolated using a spin column (i.e., a silica-gel membrane). The RNA was then treated with DNase I for 25 minutes in a 37°C water bath, to remove DNA contaminants. Purity and concentration of the RNA was tested by spectrophotometry (BioMate 5 Spectrophotometer; Thermo Spectronic, Madison, WI).
RT-PCR and Sequencing of PCR Product
To determine the presence of MMPs and TIMPs, qualitative RT-PCR was performed on total RNA isolated from CB tissue and untreated explant cultures of CBSM cells (SuperScript One-Step RT-PCR with the Platinum Taq System; Invitrogen) in accordance with the manufacturer's protocol. RT-PCR was initially performed with oligonucleotide primers previously published in the literature ( Ref.
Forward (5-3)
Reverse ( Ten percent of the RT-PCR product was used as the DNA template for the PCR reaction. PCR conditions were as follows: incubation at 94°C for 2 minutes, followed by amplification at 94°C for 30 seconds, annealing for 30 seconds, and extension at 72°C for 30 seconds for 35 cycles. A final extension was run at 72°C for 7 minutes. This reamplification was not necessary for cultures of CBSM cells. Gel electrophoresis of the PCR products was performed on a 2% agarose gel (E-gel; Invitrogen).
When the single correct band size was located, the bands were cut from the gel and purified (Gel Extraction Kit; Qiagen, Valencia, CA). DNA sequencing was then performed at the core facility of Thomas Jefferson University to confirm that the product obtained was representative of the specific MMP or TIMP. Results from the sequencing were analyzed with the BLAST program (http://www.ncbi.nlm.nih. gov/BLAST/ provided in the public domain by National Center for Biotechnology Information [NCBI], Bethesda, MD). If a band was not present, then RT-PCR was attempted with at least three to four primer sets designed by an online primer design program (e.g., Primer3: http://www.genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi).
qRT-PCR: Primer-Probe Design
For the gene of interest, the DNA sequence (GenBank; NCBI, Bethesda, MD) was used to create a primer-probe combination (Primer Express; ABI, Foster City, CA; Table 2 ). RT-PCR was performed with these primers, as described in the prior section. The PCR products (between 75 and 150 bp in length) were run on a 4% agarose gel (E-gel; Invitrogen) with a 25-bp DNA ladder (Invitrogen). DNA sequencing of the amplicons verified the specificity of the primers, as described earlier. This served as a second confirmation as to the presence of mRNA of the MMP or TIMP of interest.
Quantitative RT-PCR was performed (Prism 7000; ABI) with mastermix (TaqMan One Step RT-PCR; ABI) with GAPDH as an endogenous control (ABI). The thermocycling conditions were performed in three stages: one was cDNA synthesis of 48°C for 30 minutes; two was denaturation at 95°C for 10 minutes; and three was 40 cycles of 95°C for 15 seconds followed by annealing at 60°C for 1 minute. Results were then quantified (Prism 7000 SDS Software; ABI). We used 20 or 30 ng of total RNA to compare expression levels of MMPs and TIMPs.
Relative Quantitation
For relative quantitation normalized to GAPDH, an endogenous control, standard curves were prepared for both MMPs and GAPDHs and TIMPs and GAPDHs. Standard curves for MMP-1, -2, -14, -15, -16, -19, and -24 and their counterpart GAPDHs were constructed using a serial dilution of total RNA with a range of 0.2, 0.5, 1, 2, 5, 10, and 20 ng ( Fig. 1D ). Using three C T levels (i.e., threshold cycle, defined as the fractional cycle number at which the amount of amplified target reaches a fixed threshold) for each input amount of dilution, standard curve equations for MMPs, TIMPs, and their counterpart GAPDHs were generated ( Table 3 ). The comparative ⌬C T method was used for relative quantitation of those genes whose absolute value of the slope of log input versus ⌬C T was less than 0.1 ( Table 3 ). The relative standard curve method was used for genes that did not satisfy the criteria. The coefficient of variation (CV) was used for data reproducibility. Reproducibility of standard curves of GAPDHs obtained from those cell lines used for different genes was as follows: 4.45 to 5.57 of CV (%) for HT-1080, 2.27 to 3.61 of CV (%) for CCF-STTG1, and 0.98 to 2.38 of CV (%) for cultured TM endothelial cells. All triplicates of C T s used for the experiment showed much less than 1% CV (Table 3 ). According to the manufacturer's protocol, triplicates showing less than 2% CV are accepted for this assay (ABI).
RESULTS mRNA Expression of MMPs and TIMPs
Eleven of 21 MMPs were expressed in the CB tissue and the cultures of CBSM cells (Table 4) as determined by qualitative RT-PCR and subsequent DNA sequence confirmation (Fig. 2) . MMP-9 was not detected, but a very small amount was observed when CBSM cells were treated with latanoprost in quantitative RT-PCR. All four TIMPs were expressed by qualitative RT-PCR, and their subsequent DNA sequences were confirmed. 
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In the cultured CBSM cells, the relative level of expression of the 11 MMPs and four TIMPs was determined by the C T values in the control group. MMP-2 and -14 had very high expression levels with C T s of 24 to 26 at 20 ng of total RNA (MMP-2 Ն MMP-14); MMP-24 had high expression levels with a C T of 26 to 29; and MMP-1, -11, -15, -16, and -19 had , and -24 and GAPDH were generated with total RNA from HT-1080 cells (human fibrosarcoma cell line; ATCC, Manassas, VA), (B) standard curves for MMP-3, -11, and -17 and GAPDH were generated with total RNA from CCF STTG1 cells (human astrocytoma; ATCC), (C) standard curves for MMP-12 and GAPDH and their ⌬C T plots were generated with total RNA from hCBSM cells and (D) relative efficiency plots for TIMPs were generated with total RNA from human trabecular meshwork endothelial cells. The mRNA expression level of MMPs and TIMPs in the control and latanoprost-treated cultures was calculated with the comparative ⌬C T method, in which the absolute value of the slope of log input versus ⌬C T is Ͻ 0.1. However, the relative standard curve method was used for genes that did not satisfy the criteria. Each point in a linear line is the average of triplicate results. The equations for standard curves were generated with three C T of each input amount of dilutions, and the equations generated with ⌬C T were calculated with the average C T of target and reference genes. 
Changes in mRNA Expression of MMPs by Latanoprost Acid
Cultures of CBSM cells derived from five to six eyes of different donors were exposed to vehicle control (0.06% ethanol), 0.03, 0.3, or 30 g/mL of latanoprost free acid. (36 -39) ; ϩ/Ϫ, not detected at RT-PCR. The numbers in parenthesis are C T levels; the ranges encompass all C T levels from all five cell lines. The C T for GAPDH (i.e., endogenous control) were 21-23 for all MMPs, and TIMPs tested from all experiments.
† Individual difference in the effect of latanoprost on MMPs: DOWN, downregulation; NO, no effect; UP, upregulation. Numbers indicate number of donors. The criteria for decision of expression level are as follows: UP, 10% above control; NO, control Ϯ 10%; DOWN, 10% below control. A change of more than 10% in expression between the control and experimental levels was defined as an alteration of expression. Relative efficiencies of target and reference genes were considered equal if the absolute value of the slope of log input versus ⌬C T was less than 0.1. Thus, the relative quantitation method classified 10% variability as unchanged, according to the manufacturer's instructions. There was substantial individual variability among the donors tested, which had been encountered in previous studies of MMP and TIMP expression with latanoprost in CB. 49 Therefore, the ultimate determination of the effect of latanoprost on expression of an individual MMP or TIMP was determined by the trend of the majority (Ͼ60%) of the samples at a concentration of 0.03 g/mL ( Table  4) . The trend at the other latanoprost concentrations was determined in the same way (Fig. 1) .
Collagenases. Of the three known collagenases, collagenase-1 (MMP-1) was the only detected enzyme in this subfamily. At a pharmacologic level (0.03 g/mL) of latanoprost, the expression of MMP-1 decreased an average of 18% in all five donors. As the concentration of latanoprost increased to suprapharmacologic doses, two of five donors showed a further dose-dependent decrease in expression (Fig. 3A) .
Gelatinases. Of the two gelatinases, only gelatinase A (MMP-2) was detected. The expression of MMP-2 in three donors decreased an average of 16% in response to 0.03 g/mL of latanoprost, and as the concentration of latanoprost increased, a tendency toward decreased expression was observed (Fig. 3B) . The other two donors showed no changes in expression at 0.03 g/mL.
Stromelysins. Of the three known stromelysins, stromelysin-1 and -3 (MMP-3 and -11, respectively) mRNAs were detected. At 0.03 g/mL of latanoprost, three of five donors showed approximately 30% more MMP-3 mRNA expression, which further increased at 0.3 g/mL; 30 g/mL of latanoprost decreased the expression below baseline levels in two of these three donors. In the two other donors, the relative expression was within 10% of control in one, and there was a consistent decrease in expression at all concentrations in the other (Fig. 3C) .
MMP-11 expression was not observed to change in three donors at 0.03 g/mL of latanoprost, but as the concentration of latanoprost increased, there was a decrease in expression (Fig. 3C) . One donor showed an increase and the other a decrease of expression at all doses leading us to conclude that the expression of MMP-11 is unchanged by latanoprost.
Membrane-Type Matrix Metalloproteinases. At 0.03 g/mL, the expression of MT1-MMP (MMP-14) was consistently decreased in three donors an average of 20%, whereas the two other donors had a consistent increase. Higher doses tended not to change the trends observed at 0.03 g/mL (Fig.  3E) .
At 0.03 g/mL, the expression of MT2-MMP (MMP-15) decreased in three donors an average of 35%. The decreased expression in these four donors continued at higher concen- trations of latanoprost. The other donor showed a dose-dependent increase in expression (Fig. 3E) . The expression of MT3-MMP (MMP-16) decreased an average of 20%, in three donors at all concentrations of latanoprost. In the remaining two donors, MMP-16 expression increased in one and remained unchanged in the other at 0.03 g/mL. At higher concentrations of latanoprost, the expression of MMP-16 was less than 10% different from baseline in the remaining two (Fig. 3G) .
Only MT4-MMP (MMP-17) showed a consistent dose-dependent increase in expression in response to latanoprost in four of five donors and was unchanged in the remaining one (Fig.  3G) . At 0.03 g/mL, the average increase was 23%.
At 0.03 g/mL, the expression of MT5-MMP (MMP-24) in two donors decreased. The expression in one donor was unchanged, and in the remaining two donors expression increased, leading us to conclude that the expression of MMP-24 is unchanged. As the concentration of latanoprost increased, no trends were elucidated (Fig. 3F) .
Miscellaneous MMPs. Metalloelastase (MMP-12) had an average decrease of 24% in expression in four of five donors at 0.03 g/mL. The expression in the remaining donor increased at 0.03 g/mL of latanoprost (Fig. 3D) . The cultures from five donors were tested and MMP-12 was detected at a level too low to provide useful data for the quantitative RT-PCR assay in two of these donors; therefore, CBSM cell cultures from two additional donors were tested. At higher concentrations, MMP-12 showed a trend toward a dose-dependent decline.
At 0.03 g/mL, the expression of RASI-1 (MMP-19) decreased in two donors, was unchanged in two, and increased in the remaining donor. Higher concentrations of latanoprost did not change the trend at 0.03 g/mL (Fig. 3D ) leading us to conclude that MMP-19 expression was unchanged by latanoprost.
In summary, MMP-3 and MMP-17 tended to have an increase in mRNA expression in response to latanoprost, whereas MMP-1, -2, -12, -14, -15, and -16 decreased. There was high variability in the responses of mRNA expression of MMPs to latanoprost among donors.
Tissue Inhibitors of Matrix Metalloproteinases. The expression of TIMP-1 did not change in three of the five donors (Fig. 3H) at 0.03 g/mL. In the remaining two, levels were elevated in one and decreased in the other. At higher concentrations of latanoprost, no trend was observed.
At 0.03 g/mL, TIMP-2 expression was unchanged in two of the five donors. The expression in two other donors increased (Fig. 3I ) and expression decreased in the remaining one. As the concentration of latanoprost increased, no trend was detectable.
TIMP-3 expression increased an average of 32% in all five donors at 0.03 g/mL. The increase in expression continued in four of five donors at 0.3 g/mL (Fig. 3J) . At 30 g/mL, TIMP-3 was downregulated.
The expression of TIMP-4 did not change in three of the five donors at 0.03 g/mL, but decreased in the remaining two ( In response to pharmacologic doses of latanoprost, TIMP-3 transcription increased, whereas the transcription of TIMPs-1, -2, and -4 was not observed to change.
DISCUSSION mRNA Expression of MMPs and TIMPs
To date, this is the most comprehensive analysis of MMP and TIMP mRNA expression in human CB. The presence of mRNA and protein of MMP-1, -2, -3, and -9 have been described in human CB. 22-25,49 -51 TIMP-1 and -2 have been described at the mRNA and protein levels, whereas TIMP-3 and -4 proteins have been found in the CB. 24, 26, 51 We found the mRNA of eight other MMPs and TIMP-4. To assure the validity of our expression pattern of MMPs and TIMPs, we used oligonucleotide primers previously validated in the literature and confirmed the DNA sequence of the PCR products. We tested both tissues and explant cultures of CBSM cells. A second set of primers (those for the quantitative RT-PCR) also confirmed the expression of these genes in the CBSM cells.
The presence of nearly all known MT-MMPs points to their importance in the functioning of CBSM cells and uveoscleral outflow. All MT-MMPs can degrade ECM components and can be competitively inhibited by TIMPs.
52 MT1-MMP, along with TIMP-2, is involved in the activation of MMP-2 (gelatinase A) and MMP-13.
52-56
We could not detect expression of MMP-9, gelatinase B, in untreated or control samples, but it was induced by latanoprost at a very low level. In immunolabeling studies of human CBSM cell cultures and monkey CB tissue treated with control or latanoprost, Ocklind 23 was unable to find MMP-9. However, expression of MMP-9 in CB has been described at both the RNA 42 and protein 22, 24, 51 levels. Weinreb and Lindsey 49 found the mRNA of MMP-9 in control samples of CBSM cells. The protein of MMP-9 has been described at low levels in other studies. Using an immunohistochemical study to map the distribution of MMP-1, -2, -3, and -9 and the four TIMPs in the anterior uvea, Lan et al., 51 described MMP-9 as having moderate staining in the CB. El Shabrawi et al., 24 using CB explant organ cultures, reported that MMP-9 was barely detectable in the medium of their control cultures, and was undetectable in dexamethasone-treated cultures. In their immunohistochemical studies, they found diffuse staining throughout the CB, but much less than that found for MMP-2 and -3. 24 In the zymogram in the study by Weinreb et al., 22 MMP-9 activity was barely above background. In their Western blot analysis, a band at approximately 95 kDa was present, but was clearly weaker than the bands for the other three MMPs studied. The predominance of the band at 95 rather than 82 kDa indicated that the protein is primarily inactive. 22 If MMP-9 is expressed, it is probably expressed at extremely low levels with low activity and could vary from one individual to another. However, it appeared to be inducible with latanoprost in our studies.
Changes in MMPs and TIMPs to Latanoprost
Most of the MMPs are either downregulated or unchanged in response to latanoprost at pharmacologic concentrations. Based on the consistent increase in mRNA expression of MMP-3 (stromelysin-1) and MMP-17 (MT4-MMP), it seems that these two enzymes are important for the latanoprost-induced increase in ECM degradation. Both of these are expressed at low amounts in control samples. In trabecular meshwork, MMP-3 is involved in the ECM-mediated decrease in outflow resistance to both tert-butylhydroquinone and argon laser. 57, 58 MMP-3 may have a similar role as an effector of ECM degradation in CB after latanoprost treatment. Little is known about MMP-17. Through association with syndecan-1 on the cell surface, MMP-17 activates aggrecanase-1 (ADAMTS4), the active form of which associates with syndecan-1 through chondroitin sulfate and heparin sulfate. [59] [60] [61] MMP-17 can activate TNF-␣. [62] [63] [64] It is unclear whether MMP-17 can activate MMP-2 (pro-gelatinase A). 62, 63 Aggrecanase-1 degrades glycosaminoglycans, and its upregulation is associated with increased ECM degradation. 59 -61 It is possible that by activating aggrecanase-1, MMP-17 helps further ECM turnover in CB in response to latanoprost.
A consistent increase in TIMP-3 mRNA expression in response to latanoprost was found. TIMP-3 is the only TIMP that is sequestered in ECM to heparin-sulfate containing proteoglycans and possibly chondroitin-sulfate containing proteoglycans. [65] [66] [67] TIMP-3 is unique in its ability to inhibit TNF-␣-converting enzyme (TACE) and its ability to inhibit strongly not only MMPs but several ADAMs (a disintegrin and metalloproteinase) and ADAMTS (ADAM with thrombospondin motifs). 66 -70 TIMP-3 has also been hypothesized to function in a tissue-specific fashion as part of an acute response to remodeling stimuli and regulating ECM remodeling during the folding of epithelia. [71] [72] [73] TIMP-3 is an excellent inhibitor of MT1-MMP and MT2-MMP. 37, 74 Mutations in TIMP-3 causes Sorsby's fundus dystrophy. 75 Although TIMP-3 overexpression can cause apoptosis in some cancer cell lines, there has been no evidence that apoptosis occurs in CB in response to latanoprost treatment. 76 -78 Because TIMP-3's functions are primarily believed to be inhibitory, the upregulation of TIMP-3 may be part of a regulatory reaction to balance the latanoprost-induced increase in MMPs. However, it is also possible that its increase facilitates activation of the MMP zymogens, since TIMP-3 can bind pro-MMP-9. 27 MMP-2 and -14 were the most highly expressed MMPs in the CBSM, and both were downregulated in response to latanoprost. Thus, our results do not support that these enzymes are primarily responsible for latanoprost-mediated ECM turnover. However, further study comparing the relative levels of zymogen (i.e., pro-MMP-2) versus active MMP-2 and -14 are needed to determine the importance of MMP-2, since it is primarily regulated at activation.
We observed variability in the response to latanoprost among cultures from different donors similar to other studies of MMP-1, -2, -3, and -9 transcription after latanoprost incubation. 49 The source of this variation is unknown, but it could represent normal human variations of a mRNA that is present in very low amounts under normal conditions, donor medication history, variability inherent in the analysis methods, and normal genetic variation in response to latanoprost. 79 Clinically, there are some patients whose IOPs do not lower in response to latanoprost treatment. 80 In our study, latanoprost altered at least some of the MMPs and TIMPs in all cell lines. There was no apparent age-dependent pattern of response.
The absence of a nonresponder may simply reflect our small sample size or indicate that the cause of clinical nonresponse is at a level beyond transcription in the CB.
Weinreb and Lindsey 49 found MMP-1 increased (in all five donors at 6 hours, but decreased at 24 hours), MMP-2 decreased (in three of five donors), MMP-3 increased (in three of five donors), and MMP-9 increased (in four of five donors) in response to latanoprost. Our results are consistent with regards to MMP-1, -2 and -3 at 24 hours.
In the other study examining the transcriptional activity of TIMP-1 and -2 after latanoprost, Anthony et al. 26 found that TIMP-1 was upregulated at 24 hours, which we did not find. They also found that TIMP-2 was mildly elevated at 6 hours and was unchanged at 24 hours, which agrees with our results. At 6 hours, the elevation was 6% to 11%, which would have been interpreted as unchanged with our criteria. 26 At the protein level, El Shabawri et al. 24 found no change in either TIMP-1 or -2 after latanoprost or dexamethasone treatment.
Our results indicated that MMP-3, -9, and -17 may be responsible for the alteration in the ECM with latanoprost treatment. TIMP-3 was the only TIMP consistently altered by latanoprost. Examination of MMP/TIMP mRNA expression at only one time point is a limitation of this study. In addition, latanoprostmediated changes in MMP and TIMP activity may be regulated by posttranscriptional events during biosynthesis and by extracellular activation, kinetic inhibition, and degradation. However, in the CB, latanoprost appears to shift the balance of MMPs and TIMPs toward greater levels of MMPs, resulting in the observed changes in the ECM.
